A few things on my calendar:
• A resolution / another band aid to government budget issues this week
• All of the silly class actions evaporate Oct 22
• Customary pre earnings announcements to massage investor interest (some potential nuggets)
• Earnings 1st week of November that will bump the trailing twelve month revenue up again ($5-$6 valuation)
• Capitulation when they decide to cut their losses, lots of sub $2 short interest
• Reversing of the pendulum, manipulation compounded by over reaction introduced too many shares to the market, it wants to swing back toward the 100 dma. Oscillating around the 100 should give you an amplitude around 2.70, and a subsequent peak in the $5.50 - $6.00 range sometime in Dec. BIOL was simply undervalued, and oversold.
• Further out I'm looking for a permanent marriage of BIOL, and NewTom in some way shape or form, if it's not something BIOL is planning yet, they should be. That would be a good reason to create a secondary offering to support the acquisition of what would likely be an accretive purchase. Forrest Gump would say "they go together like peas and carrots"
Guidance of 68 M rev for '13 against 34.8, falls right around my previous $5.80 low end valuation. Revenue growth will nullify the recent 2.7M dilution. Stick with 5.80!
Wow another string of incorrect answers
1. Government has no effect on Biolase.
2. Class actions will be around through discovery which will take months if not years.
3. One has to have yearly earnings to compute PE.
4. There will be no "earnings in 3Q13. Revenues may rise, but that valuation theory has been disproved.
5. There is practically no sub $2 short interest. Look at shorted shares on NASDAQ.com. Almost no change since August 1st.
6. 100 dma? ROFLMAO. First you were pumping the 30 dma and then the 50 dma and now the 100? Things changed and will not be dramatically change this year. One needs to wait for 2/14 for the possibility of a a decent move. Biolase is trading just a little above fair value today, IMHO.
7. Biolase will not be a buyer. They don't have the cash or management ability. IMHO, Biolase's shareholders best changes is for freddie to admit his short comings as a manager and let the company be bought.
8. Tinkerbell's use of price/sales ratios for forecasting Biolase's potential has been dramatically dis-proven. Why she can't admit this to herself is beyond me.